Biomimesys
Three projects for HCS Pharma with ONCOLille Institute thanks to Plan France Relance and Région Hauts-de-France
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…